newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

  • Ascentage Pharma presented seventeen clinical updates, including eight poster presentations, at the 31st European Hematology Association Congress (EHA2026) in Stockholm from June 11 to 14, 2026.
  • Presentations highlighted data on olverembatinib (HQP1351), a third-generation BCR-ABL1 inhibitor approved in China, & lisaftoclax (APG-2575), a China-developed Bcl-2 selective inhibitor approved in China.
  • Olverembatinib demonstrated deep, durable responses in chronic-phase CML patients resistant or intolerant to first-line TKIs, supporting its use as a second-line treatment option.
  • In CML patients with multiline TKI resistance & co-occurring high-risk mutations, olverembatinib showed positive clinical activity, including efficacy in patients with ASXL1 mutations after ponatinib or asciminib failure.
  • A controlled trial found switching to olverembatinib significantly improved 6-month major molecular response rates (54.3% vs 10.0%) compared to continuing prior TKI therapy in patients who failed at least two previous TKIs.
  • The Phase III POLARIS-1 study in newly diagnosed Ph+ ALL showed a 94.4% complete response rate & a 93.1% MRD-negative rate by cycle 9 for olverembatinib combined with low-intensity chemotherapy.
  • A Phase Ib study of olverembatinib combined with lisaftoclax in pediatric relapsed/refractory Ph+ ALL reported an 88.9% overall response rate & evidence of CNS penetration with a manageable safety profile.
  • Real-world data for lisaftoclax in myeloid neoplasms indicated a 72% CR/CRi rate in AML patients, with 100% response in those harboring NPM1 mutations.
  • Pivotal Phase II data for lisaftoclax in CLL/SLL showed a 23.9-month median progression-free survival & a 62.5% overall response rate in patients refractory to BTK inhibitors.
  • Baseline characteristic analyses for lisaftoclax in CLL/SLL identified complex karyotype & tumor size as independent risk factors for shorter progression-free survival.
  • Both assets are currently under investigation for US FDA approval, with registrational Phase III trials ongoing for olverembatinib in CML & Ph+ ALL & lisaftoclax in CLL/SLL, AML, & MDS.